Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs

Journal of Experimental Medicine

Volumn 189, Issue 9, 1999, Pages 1451-1460

  Kayagaki, Nobuhiko ^a   Yamaguchi, Noriko ^a,b   Nakayama, Masafumi ^a   Hiroshi, Eto ^c   Okumura, Ko ^a,b   Yagita, Hideo ^a,b  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytotoxic T lymphocyte; Cytotoxicity; Renal cell carcinoma; TRAIL; Type I interferon

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY DNA; CYTOKINE; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 2; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; KIDNEY CARCINOMA; NORTHERN BLOTTING; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANTIGENS, CD3; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; JURKAT CELLS; LIGANDS; MEMBRANE GLYCOPROTEINS; RECEPTOR-CD3 COMPLEX, ANTIGEN, T-CELL; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033519303     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.189.9.1451     Document Type: Article

References (47)

1. Wiley, S.R., K. Schooley, P.J. Smolak, W.S. Din, C.P. Huang, J.K. Nicholl, G.R. Sutherland, T.D. Smith, C. Rauch, C.A. Smith, and R.G. Goodwin. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:673-682.
2. Pitti, R.M., S.A. Marsters, S. Ruppert, C.J. Donahue, A. Moore, and A. Ashkenazi. 1996. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271:12687-12690.
3. Thomas, W.D., and P. Hersey. 1998. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J. Immunol. 161:2195-2200.
4. Nagata, S. 1997. Apoptosis by death factor. Cell. 88:355-365.
5. Pan, G., K. O'Rourke, A.M. Chinnaiyan, R. Gentz, R. Ebner, J. Ni, and V.M. Dixit. 1997. The receptor for the cytotoxic ligand TRAIL. Science. 276:111-113.
6. Sheridan, J.P., S.A. Marsters, R.M. Pitti, A. Gurney, M. Skubatch, D. Baldwin, L. Ramakrishnan, C.L. Gray, K. Baker, W.I. Wood, et al. 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 277:818-821.
7. Sheikh, M.S., T.F. Burns, Y. Huang, G.S. Wu, S. Amundson, K.S. Brooks, A.J. Fornace, Jr., and W.S. el-Deiry. 1998. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor α. Cancer Res. 58:1593-1598.
8. Pan, G., J. Ni, Y.F. Wei, G. Yu, R. Gentz, and V.M. Dixit. 1997. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 277:815-818.
9. Degli-Esposti, M.A., W.C. Dougall, P.J. Smolak, J.Y. Waugh, C.A. Smith, and R.G. Goodwin. 1997. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 7:813-820.
10. Ashkenazi, A., and V.M. Dixit. 1998. Death receptors: signaling and modulation. Science. 281:1305-1308.
11. Kägi, D., F. Vignaux, B. Ledermann, K. Burki, V. Depraetere, S. Nagata, H. Hengartner, and P. Golstein. 1994. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 265:528-530.
12. Kojima, H., N. Shinohara, S. Hanaoka, Y. Someya-Shirota, Y. Takagaki, H. Ohno, T. Saito, T. Katayama, H. Yagita, K. Okumura, et al. 1994. Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity. 1:357-364.
13. Lowin, B., M. Hahne, C. Mattmann, and J. Tschopp. 1994. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature. 370:650-652.
14. Kägi, D., B. Ledermann, K. Burki, R.M. Zinkernagel, and H. Hengartner. 1996. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu. Rev. Imnmnol. 14: 207-232.
15. van den Broek, M.E., D. Kägi, F. Ossendorp, R. Toes, S. Vamvakas, W.K. Lutz, C.J. Melief, R.M. Zinkernagel, and H. Hengartner. 1996. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184:1781-1790.
16. Davidson, W.F., T. Giese, and T.N. Fredrickson. 1998. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J. Exp. Med. 187: 1825-1838.
17. Braun, M.Y., B. Lowin, L. French, H. Acha-Orbea, and J. Tschopp. 1996. Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J. Exp. Med. 183:657-661.
18. Hattori, K., T. Hirano, H. Miyajima, N. Yamakawa, M. Tateno, K. Oshimi, N. Kayagaki, H. Yagita, and K. Okumura. 1998. Differential effects of anti-Fas ligand and antitumor necrosis factor a antibodies on acute graft-versus-host disease pathologies. Blood. 91:4051-4055.
19. Seino, K., N. Kayagaki, K. Takeda, K. Fukao, K. Okumura, and H. Yagita. 1997. Contribution of Fas ligand to T cell-mediated hepatic injury in mice. Gastroenterology. 113:1315-1322.
20. + T cell-mediated cytotoxicity. J. Immunol. 162:2639-2647.
21. Morris, A., and I. Zvetkova. 1997. Cytokine research: the interferon paradigm. J. Clin. Pathol. 50:635-639.
22. Gresser, I. 1997. Wherefore interferon? J. Leukocyte Biol. 61: 567-574.
23. Strander, H. 1986. Interferon treatment of human neoplasia. Adv. Cancer Res. 46:1-265.
24. Gutterman, J.U. 1994. Cytokine therapeutics: lessons from interferon α. Proc. Natl. Acad. Sci. USA. 91:1198-1205.
25. Okada, Y., K. Gohji, S. Kamidono, and O. Tachiwaki. 1986. Establishment and characterization of a cell line (KO-RCC-1) from a human renal cell carcinoma. Jpn. J. Urol. 77:780-785.
26. Kataoka, T., N. Shinohara, H. Takayama, K. Takaku, S. Kondo, S. Yonehara, and K. Nagai. 1996. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J. Immunol. 156:3678-3686.
27. Kayagaki, N., A. Kawasaki, T. Ebata, H. Ohmoto, S. Ikeda, S. Inoue, K. Yoshino, K. Okumura, and H. Yagita. 1995. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182:1777-1783.
28. Miyatake, S., H. Nakano, S.Y. Park, T. Yamazaki, K. Takase, H. Matsushime, A. Kato, and T. Saito. 1995. Induction of G1 arrest by down-regulation of cyclin D3 in T cell hybridomas. J. Exp. Med. 182:401-408.
29. Nakata, M., A. Kawasaki, M. Azuma, K. Tsuji, H. Matsuda, Y. Shinkai, H. Yagita, and K. Okumura. 1992. Expression of perforin and cytolytic potential of human peripheral blood lymphocyte subpopulations. Int. Immunol. 4:1049-1054.
30. de Boer, M., A. Kasran, J. Kwekkeboom, H. Walter, P. Vandenberghe, and J.L. Ceuppens. 1993. Ligation of B7 with CD28/CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells. Eur. J. Immunol. 23:3120-3125.
31. Ye, W., J.D. Young, and C.C. Liu. 1996. Interleukin-15 induces the expression of mRNAs of cytolytic mediators and augments cytotoxic activities in primary murine lymphocytes. Cell. Immunol. 174:54-62.
32. + lymphoid population capable of eliciting cytolysis against Fas-positive tumor cells. J. Immunol. 159:2599-2605.
33. Tsutsui, H., K. Nakanishi, K. Matsui, K. Higashino, H. Okamura, Y. Miyazawa, and K. Kaneda. 1996. IFN-γ-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J. Immunol. 157:3967-3973.
34. Jeremias, I., I. Herr, T. Boehler, and K.M. Debatin. 1998. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur. J. Immunol 28:143-152.
35. Darnell, J.E., Jr., I.M. Kerr, and G.R. Stark. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 264:1415-1421.
36. + T lymphocytes are required for the synergistic action of interferon-α/β and adoptively transferred immune cells in the inhibition of visceral ESb metastases. Cancer Res. 55:6133-6139.
37. + T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-γ-producing TS/A cells. J. Immunol. 153:4604-4615.
38. Kaido, T., I. Gresser, C. Maury, M.T. Maunoury, F. Vignaux, and F. Belardelli. 1993. Sensitized T lymphocytes render DBA/2 beige mice responsive to IFN γ/β therapy of Friend erythroleukemia visceral metastases. Int. J. Cancer. 54: 475-481.
39. + T cells and IFN-γ/β. Int. J. Cancer. 57:538-543.
40. Romero, P., P. Rod Dunbar, D. Valmori, M. Pittet, G.S. Ogg, D. Rimoldi, J.L. Chen, D. Lienard, J.C. Cerottini, and V. Cerundolo. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188:1641-1650.
41. Jantzer, P., and D.J. Schendel. 1998. Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo. Cancer Res. 58:3078-3086.
42. Yagita, H., N. Kayagaki, A. Kawasaki, and K. Okumura. 1997. CD95 ligand pre-workshop report. In Leukocyte Typing VI. Garland Publishing, Inc., New York. 105-109.
43. Tanaka, M., T. Itai, M. Adachi, and S. Nagata. 1998. Down-regulation of Fas ligand by shedding. Nat. Med. 4:31-36.
44. Schneider, P., N. Holler, J.L. Bodmer, M. Hahne, K. Frei, A. Fontana, and J. Tschopp. 1998. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187:1205-1213.
45. van den Broek, M.F., U. Muller, S. Huang, R.M. Zinkernagel, and M. Aguet. 1995. Immune defence in mice lacking type I and/or type II interferon receptors. Immunol. Rev. 148: 5-18.
46. Ambras, J.L., B.J. Poiesz, M.A. Lillie, I. Stadler, L.A. Di Berardino, and K.C. Chadha. 1989. Interferon and interferon inhibitor levels in patients infected with varicella-zoster virus, acquired immunodeficiency syndrome, acquired immunodeficiency syndrome-related complex, or Kaposi's sarcoma, and in normal individuals. Am. J. Med. 87:405-407.
47. Katsikis, P.D., M.E. Garcia-Ojeda, J.F. Torres-Roca, I.M. Tijoe, C.A. Smith, and L.A. Herzenberg. 1997. Interleukin-1 β converting enzyme-like protease involvement in Fas-induced and activation-induced peripheral blood T cell apoptosis in HIV infection. TNF-related apoptosis-inducing ligand can mediate activation-induced T cell death in HIV infection. J. Exp. Med. 186:1365-1372.